petBrain: a new pipeline for amyloid, Tau tangles and neurodegeneration quantification using PET and MRI.

IF 7.6 1区医学 Q1 CLINICAL NEUROLOGY

Alzheimer's Research & Therapy Pub Date : 2025-09-30 DOI:10.1186/s13195-025-01839-y

Pierrick Coupé, Boris Mansencal, Floréal Morandat, Sergio Morell-Ortega, Nicolas Villain, Jose V Manjón, Vincent Planche

{"title":"petBrain: a new pipeline for amyloid, Tau tangles and neurodegeneration quantification using PET and MRI.","authors":"Pierrick Coupé, Boris Mansencal, Floréal Morandat, Sergio Morell-Ortega, Nicolas Villain, Jose V Manjón, Vincent Planche","doi":"10.1186/s13195-025-01839-y","DOIUrl":null,"url":null,"abstract":"Introduction: Quantification of amyloid plaques (A), neurofibrillary tangles (T2), and neurodegeneration (N) using PET and MRI is critical for Alzheimer's disease (AD) diagnosis and prognosis. Existing pipelines face limitations regarding processing time, tracer variability handling, and multimodal integration.Methods: We developed petBrain, a novel end-to-end processing pipeline for amyloid-PET, tau-PET, and structural MRI. It leverages deep learning-based segmentation, standardized biomarker quantification (Centiloid, CenTauR, HAVAs), and simultaneous estimation of A, T2, and N biomarkers. It is implemented in a web-based format, requiring no local computational infrastructure and software usage knowledge.Results: petBrain provides reliable, rapid quantification with results comparable to existing pipelines for A and T2, showing strong concordance with data processed in ADNI databases. The staging and quantification of A/T2/N by petBrain demonstrated good agreements with CSF/plasma biomarkers, clinical status and cognitive performance.Discussion: petBrain represents a powerful open platform for standardized AD biomarker analysis, facilitating clinical research applications.","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":"17 1","pages":"209"},"PeriodicalIF":7.6000,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482854/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's Research & Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13195-025-01839-y","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Quantification of amyloid plaques (A), neurofibrillary tangles (T₂), and neurodegeneration (N) using PET and MRI is critical for Alzheimer's disease (AD) diagnosis and prognosis. Existing pipelines face limitations regarding processing time, tracer variability handling, and multimodal integration.

Methods: We developed petBrain, a novel end-to-end processing pipeline for amyloid-PET, tau-PET, and structural MRI. It leverages deep learning-based segmentation, standardized biomarker quantification (Centiloid, CenTauR, HAVAs), and simultaneous estimation of A, T₂, and N biomarkers. It is implemented in a web-based format, requiring no local computational infrastructure and software usage knowledge.

Results: petBrain provides reliable, rapid quantification with results comparable to existing pipelines for A and T₂, showing strong concordance with data processed in ADNI databases. The staging and quantification of A/T₂/N by petBrain demonstrated good agreements with CSF/plasma biomarkers, clinical status and cognitive performance.

Discussion: petBrain represents a powerful open platform for standardized AD biomarker analysis, facilitating clinical research applications.

查看原文本刊更多论文

petBrain：利用PET和MRI对淀粉样蛋白、Tau缠结和神经变性进行量化的新途径。

应用PET和MRI定量检测淀粉样斑块(A)、神经原纤维缠结（T2）和神经变性(N)对阿尔茨海默病（AD）的诊断和预后至关重要。现有管道面临着处理时间、示踪剂可变性处理和多模式集成等方面的限制。方法：我们开发了petBrain，一种新的端到端处理管道，用于淀粉样蛋白pet， tau-PET和结构MRI。它利用基于深度学习的分割，标准化的生物标志物量化（Centiloid, CenTauR, HAVAs），以及A， T2和N生物标志物的同时估计。它以基于web的格式实现，不需要本地计算基础设施和软件使用知识。结果：petBrain提供了可靠、快速的定量，其结果与现有的A和T2管道相当，与ADNI数据库中处理的数据具有很强的一致性。petBrain对A/T2/N的分期和定量与脑脊液/血浆生物标志物、临床状态和认知表现具有良好的一致性。讨论：petBrain代表了一个强大的标准化AD生物标志物分析开放平台，促进临床研究应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer's Research & Therapy 医学-神经病学

CiteScore

13.10

自引率

3.30%

发文量

172

审稿时长

>12 weeks

期刊介绍： Alzheimer's Research & Therapy is an international peer-reviewed journal that focuses on translational research into Alzheimer's disease and other neurodegenerative diseases. It publishes open-access basic research, clinical trials, drug discovery and development studies, and epidemiologic studies. The journal also includes reviews, viewpoints, commentaries, debates, and reports. All articles published in Alzheimer's Research & Therapy are included in several reputable databases such as CAS, Current contents, DOAJ, Embase, Journal Citation Reports/Science Edition, MEDLINE, PubMed, PubMed Central, Science Citation Index Expanded (Web of Science) and Scopus.